Following up on the FDA's decision to spurn the experimental heart drug Certriad back in March, Abbott and AstraZeneca announced that they were dumping the program. Regulators had asked for more data on the drug but the pharma companies said that the delay would kill the drug's market potential. This is AZ's third setback in the past week. Story